Literature DB >> 19184450

Studies on mefenamic acid microparticles: formulation, in vitro release, and in situ studies in rats.

Ferhan Sevgi1, Aysu Yurdasiper, Buket Kaynarsoy, Ezgi Turunç, Tamer Güneri, Ayfer Yalçin.   

Abstract

In this study, we investigated the in vitro characteristics of mefenamic acid (MA) microparticles as well as their effects on DNA damage. MA-loaded chitosan and alginate beads were prepared by the ionotropic gelation process. Microsponges containing MA and Eudragit RS 100 were prepared by quasi-emulsion solvent diffusion method. The microparticles were characterized in terms of particle size, surface morphology, encapsulation efficiency, and in vitro release profiles. Most of the formulation variables manifested an influence on the physical characteristics of the microparticles at varying degrees. We also studied the effects of MA, MA-loaded microparticles, and three different polymers on rat brain cortex DNA damage. Our results showed that DNA damage was higher in MA-loaded Eudragit microsponges than MA-loaded biodegradable chitosan or alginate microparticles.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19184450      PMCID: PMC2663673          DOI: 10.1208/s12249-008-9183-0

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  32 in total

1.  Microencapsulation of ibuprofen and Eudragit RS 100 by the emulsion solvent diffusion technique.

Authors:  D Perumal
Journal:  Int J Pharm       Date:  2001-05-07       Impact factor: 5.875

2.  Physicochemical and crystallographic characterization of mefenamic acid complexes with alkanolamines.

Authors:  Liang Fang; Sachihiko Numajiri; Daisuke Kobayashi; Hideo Ueda; Koji Nakayama; Hiroshi Miyamae; Yasunori Morimoto
Journal:  J Pharm Sci       Date:  2004-01       Impact factor: 3.534

3.  The "high solubility" definition of the current FDA Guidance on Biopharmaceutical Classification System may be too strict for acidic drugs.

Authors:  Mehran Yazdanian; Katherine Briggs; Corinne Jankovsky; Amale Hawi
Journal:  Pharm Res       Date:  2004-02       Impact factor: 4.200

4.  Drug targeting using non-magnetic and magnetic albumin-globulin mix microspheres of mefenamic acid.

Authors:  J K Lalla; P L Ahuja
Journal:  J Microencapsul       Date:  1991 Jan-Mar       Impact factor: 3.142

5.  Design and evaluation of colon specific drug delivery system containing flurbiprofen microsponges.

Authors:  Mine Orlu; Erdal Cevher; Ahmet Araman
Journal:  Int J Pharm       Date:  2006-03-29       Impact factor: 5.875

6.  Linearization of dissolution rate curves by the Weibull distribution.

Authors:  F Langenbucher
Journal:  J Pharm Pharmacol       Date:  1972-12       Impact factor: 3.765

7.  Establishment of sink conditions in dissolution rate determinations. Theoretical considerations and application to nondisintegrating dosage forms.

Authors:  M Gibaldi; S Feldman
Journal:  J Pharm Sci       Date:  1967-10       Impact factor: 3.534

8.  Investigations on mefenamic acid sustained release tablets with water-insoluble gel.

Authors:  S Güngör; A Yildiz; Y Ozsoy; E Cevher; A Araman
Journal:  Farmaco       Date:  2003-05

9.  Mefenamic acid bi-directionally modulates the transient outward K+ current in rat cerebellar granule cells.

Authors:  Man Zhang; Wen-Jie Shi; Xiao-Wei Fei; Ya-Rong Liu; Xi-Min Zeng; Yan-Ai Mei
Journal:  Toxicol Appl Pharmacol       Date:  2007-09-19       Impact factor: 4.219

10.  A comparative histological study of alginate beads as a promising controlled release delivery for mefenamic acid.

Authors:  Ferhan Sevgi; Buket Kaynarsoy; Mine Ozyazici; Cetin Pekcetin; Dogan Ozyurt
Journal:  Pharm Dev Technol       Date:  2008       Impact factor: 3.133

View more
  1 in total

1.  Preparation and Determination of Drug-Polymer Interaction and In-vitro Release of Mefenamic Acid Microspheres Made of CelluloseAcetate Phthalate and/or Ethylcellulose Polymers.

Authors:  Mitra Jelvehgari; Davoud Hassanzadeh; Farhad Kiafar; Badir Delf Loveym; Sara Amiri
Journal:  Iran J Pharm Res       Date:  2011       Impact factor: 1.696

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.